Hartana et al., 2022 - Google Patents
Immune correlates of HIV-1 reservoir cell decline in early-treated infantsHartana et al., 2022
View HTML- Document ID
- 2110301837967752522
- Author
- Hartana C
- Garcia-Broncano P
- Rassadkina Y
- Lian X
- Jiang C
- Einkauf K
- Maswabi K
- Ajibola G
- Moyo S
- Mohammed T
- Maphorisa C
- Makhema J
- Yuki Y
- Martin M
- Bennett K
- Jean-Philippe P
- Viard M
- Hughes M
- Powis K
- Carrington M
- Lockman S
- Gao C
- Xu G
- Kuritzkes D
- Shapiro R
- Lichterfeld M
- Publication year
- Publication venue
- Cell Reports
External Links
Snippet
Initiation of antiretroviral therapy (ART) in infected neonates within hours after birth limits viral reservoir seeding but does not prevent long-term HIV-1 persistence. Here, we report parallel assessments of HIV-1 reservoir cells and innate antiviral immune responses in a …
- 241000713772 Human immunodeficiency virus 1 0 title abstract description 74
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hartana et al. | Immune correlates of HIV-1 reservoir cell decline in early-treated infants | |
| Sun et al. | Phenotypic signatures of immune selection in HIV-1 reservoir cells | |
| Simonetti et al. | Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA | |
| Scully et al. | Sex-based differences in human immunodeficiency virus type 1 reservoir activity and residual immune activation | |
| Jiang et al. | Distinct viral reservoirs in individuals with spontaneous control of HIV-1 | |
| Morou et al. | Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease | |
| Austin et al. | Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation | |
| Baxter et al. | Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals | |
| Kuo et al. | Anti-apoptotic protein BIRC5 maintains survival of HIV-1-infected CD4+ T cells | |
| Abdel-Mohsen et al. | CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells | |
| Laydon et al. | Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach | |
| Zak et al. | Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity | |
| Kløverpris et al. | Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression | |
| O'Brien et al. | HLA and AIDS: a cautionary tale | |
| Regoes et al. | The HIV coreceptor switch: a population dynamical perspective | |
| Hjalgrim et al. | HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma | |
| Quigley et al. | Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF | |
| Gantner et al. | HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections | |
| Chiu et al. | Sprouty-2 regulates HIV-specific T cell polyfunctionality | |
| Zerbato et al. | Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency | |
| Seclén et al. | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists | |
| Carrico et al. | Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection | |
| Riveira-Munoz et al. | Increased expression of SAMHD1 in a subset of HIV-1 elite controllers | |
| Hey-Nguyen et al. | Quantification of residual germinal center activity and HIV-1 DNA and RNA levels using fine needle biopsies of lymph nodes during antiretroviral therapy | |
| de Armas et al. | Single cell profiling reveals PTEN overexpression in influenza-specific B cells in aging HIV-infected individuals on anti-retroviral therapy |